Industry Briefs: September 24, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: September 24, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

AMRI has entered into an agreement with Knopp Biosciences to provide various discovery-related services that include medicinal chemistry, drug metabolism and pharmacokinetics, and computer-aided drug discovery, as part of AMRI’s Smartsourcing platform. Read More

Baxter International and Onconova Therapeutics have entered into a European licensing agreement for rigosertib, a targeted anticancer compound currently in a Phase III study for the treatment of a group of rare hematologic malignancies called myelodysplastic syndromes and in a Phase II/III study for pancreatic cancer. Read More

BD Medical has introduced BD Ultra-Fine Nano 4-mm Pen Needles with PentaPoint needle technology, which is designed to enhance patient comfort and improve patient adherence in diabetes care. Read More

Bristol-Myers Squibb and Vanderbilt University have signed a collaboration agreement for the discovery, development, and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators or PAMs, for treating Parkinson’s disease. Read More

Carbogen AMCIS and ADC Biotechnology have agreed to provide customers with development and manufacturing services for antibody drug conjugates. Read More

Cedarburg Hauser Pharmaceuticals has expanded the capacity of its Wisconsin-based API manufacturing plant. Read More

Evotec has entered into a multiyear compound-management agreement with the National Institutes of Health (NIH), Department of Health and Human Services, for the operation of a small-molecule repository. The contract (funded entirely by NIH) will cover a period of up to 10 years and has a total estimated value of up to EUR 60 million ($75 million). Read More

Jubilant HollisterStier’s contract manufacturing and services division has launched an analytical services unit that will provide laboratory method development and related analytical testing as part of its integrated service offerings. Read More

Sanofi and the TB Alliance have announced a research collaboration agreement for the discovery and development of novel compounds against tuberculosis. Read More

Valeant Pharmaceuticals International has acquired Visudyne (verteporfin), for treating abnormal growth of leaky blood vessels in the eye caused by wet age-related macular degeneration, from QLT. Read More

People News

Althea Technologies has announced several role changes for members of its executive team, including: Rick Hancock to the position of president and CEO, Chris Duffy to senior vice-president of operations, and E.J. Brandreth to senior vice-president of quality and regulatory. Read More

Capsugel has announced the expansion of its executive leadership team, including: John Shroyer as senior vice-president and chief financial officer, Erasmo Schutzer as senior vice-president and chief marketing officer, Ian Robertson leads Capsugel’s global information technology and systems capabilities as Capsugel’s senior vice-president and chief information officer, Christopher Game as senior vice-president and chief procurement officer, John Cullivan as senior vice-president of corporate business development and strategy, Amit Patel as senior vice-president and president of the newly created dosage form solutions business unit, and Donal Loughrey as senior vice-president of operations and supply chain. Read More

OsoBio BioPharmaceuticals Manufacturing has appointed Robert Cashman as vice-president of business development. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here